SignalEarnings
United Therapeutics missed Q3 EPS at $5.71 vs $6.04 consensus even with revenue up 4.1% to $832M. R&D jumped to $279.2M from $127.5M on the Thymmune IPR&D deal, and management flagged competitive pres
United Therapeutics missed Q3 EPS at $5.71 vs $6.04 consensus even with revenue up 4.1% to $832M. R&D jumped to $279.2M from $127.5M on the Thymmune IPR&D deal, and management flagged competitive pres
What changed
United Therapeutics missed Q3 EPS at $5.71 vs $6.04 consensus even with revenue up 4.1% to $832M. R&D jumped to $279.2M from $127.5M on the Thymmune IPR&D deal, and management flagged competitive pres
Why it matters
United Therapeutics missed Q3 EPS at $5.71 vs $6.04 consensus even with revenue up 4.1% to $832M. R&D jumped to $279.2M from $127.5M on the Thymmune IPR&D deal, and management flagged competitive pres — impact context not separately stored; see What changed.